Skip to main content

Consolidated Interim Report 1 January – 30 June 2025

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Consolidated Interim Report 1 January – 30 June 2025
Key points from the H1-2025 report (period 1 January – 30 June 2025)

14 August 2025
Announcement no. 9

On 14 August 2025, the Board of Directors and the Executive Board of Pharma Equity Group A/S (“PEG”, “The Company” or the “Group”) considered and approved the interim report for the Group for the period 1 January – 30 June 2025 (“H1 2025 report”), which can be summarized as follows:

The headlines for the period can be summarized as follows

  • The Company has launched a new strategy to drive growth and shareholder returns.
  • On 1 April 2025, Christian Henrik Tange was appointed as the new CEO of Pharma Equity Group and Sebastian Bo Jakobsen was appointed as CEO of the subsidiary Reponex Pharmaceuticals A/S
  • The company continues the dialogue with potential licensing partners.
  • Clinical trial applications for RNX-011 (peritonitis) and the clinical trial application for RNX-051 (Colorectal Adenoma and Colon Cancer) have been submitted to the Danish authorities in H1 2025.
  • The profit for the period of 1 January – 30 June 2025 amounts to DKK -9.5 million, which is in line with expectations..

                                                                                            H1-2025 TDKK          H1-2024 TDKK

Profit/Loss                                                                                -9.495                         -12.901

Receivable Portinho S.A.                                                          58.000                        58.000

Cash and cash equivalents                                                       702                             863

Total Assets                                                                               62.299                        63.169

Equity                                                                                        39.379                        12.432

Convertible Loans                                                                     15.234                        18.511

  • The result for H1-2025 was DKK -9.5 million (H1-2024: DKK -12.9 million).
  • Equity as of 30 June 2025 is DKK 39.4 million (30. June 2024: DKK 12.4 million)
  • Cash and cash equivalents as of 30 June 2025 are DKK 0.7 million (30 June 2024: DKK 0.9 million)

Online presentation of the H1-2025 report
At 11:00 a.m. today, 14 August 2025, CEO Christian Henrik Tange invites you to an online presentation of the H1 2025 report for the period 1 January 2025 – 30 June 2025 and significant events so far in 2025. Registration is free for everyone and can be done via link:
https://www.linkedin.com/feed/update/urn:li:activity:7345408645636993027

Contact person – Investor Relations
Any questions regarding the H1 2025 report can be directed to the Company’s CEO Christian Henrik Tange, by email investor@pharmaequitygroup.com.

On the Company’s website www.pharmaequitygroup.com further information and all published company announcements can be found.

Hørsholm 14 August 2025
Christian Vinding Thomsen, Chairman                                                 Christian Henrik Tange CEO



About Pharma Equity Group A/S 

Pharma Equity Group (PEG) is a dynamic life sciences investment and development firm listed on the Nasdaq Copenhagen stock exchange. PEG is dedicated to identifying, acquiring, and advancing innovations across pharmaceuticals (Pharma), medical technology (MedTech), and other medical devices, with a strategic focus on early-stage opportunities, particularly those emerging from Scandinavian research institutions. By leveraging strategic capital allocation, robust governance including a dedicated Investment Committee, and an extensive industry network, PEG aims to transform groundbreaking ideas into impactful healthcare solutions and products. The company is committed to building a balanced portfolio that delivers ongoing value creation and supports long-term growth for the benefit of patients, healthcare systems, and its investors.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.